Clinical and histopathological data from a 3-year real-world follow-up of dupilumab in palmoplantar pustulosis
Description
Supplementary Table S1. Demographic and clinical information for palmoplantar pustulosis patients. Note: These data were partially reported in our prior publication in Allergy (PMID: 38193274) and are included here for continuity. Supplementary Figure S1. Representative H&E-stained sections from three patients with palmoplantar pustulosis (Patient No. 1–3), showing intraepidermal neutrophilic pustules, compact hyperkeratosis, psoriasiform hyperplasia, and superficial perivascular inflammatory infiltrates. All images at 10× magnification. Scale bar = 200 μm. Supplementary Figure S2. Patient No. 2 with palmoplantar pustulosis (PPP). Serial clinical photographs at (A) baseline (pre-dupilumab, Month 0), (B) Month 18 on dupilumab, and (C) Month 36 on dupilumab, demonstrating sustained control of palmar (upper panels) and plantar (lower panels) involvement. Supplementary Figure S3. Patient No. 10 with palmoplantar pustulosis (PPP). Serial clinical photographs at (A) baseline (pre-dupilumab, Month 0), (B) Month 18 on dupilumab, and (C) Month 36 on dupilumab, demonstrating sustained control of palmar (upper panels) and plantar (lower panels) involvement.